Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
483.43
+8.23 (+1.73%)
Streaming Delayed Price
Updated: 1:32 PM EDT, Jun 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of
↗
March 04, 2026
These two biotechs have a lot in common. Their differences are even more pronounced.
Via
The Motley Fool
Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?
↗
March 02, 2026
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.
Via
The Motley Fool
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows High Technical and Setup Ratings for Potential Breakout
↗
February 28, 2026
Via
Chartmill
2 Top Healthcare Stocks to Buy in February
↗
February 26, 2026
Patience should pay off with these two healthcare giants.
Via
The Motley Fool
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance
↗
February 12, 2026
Via
Chartmill
Forget Centessa Pharmaceuticals: This Rare‑Disease Specialist Has a Superior Portfolio and Pipeline
↗
February 26, 2026
One of these is not like the other.
Via
The Motley Fool
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...
Via
MarketMinute
Topics
Intellectual Property
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question
February 24, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing...
Via
StockStory
The Ultimate Biotech Stock to Buy With $500 Right Now
↗
February 24, 2026
This biotech powerhouse could maintain its strength for the long term.
Via
The Motley Fool
Topics
Intellectual Property
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?
↗
February 22, 2026
Even a great stock has a ceiling.
Via
The Motley Fool
Topics
Intellectual Property
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices
↗
February 20, 2026
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
Via
The Motley Fool
Topics
ETFs
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
↗
February 19, 2026
Via
MarketBeat
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
February 19, 2026
Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from...
Via
StockStory
Topics
Earnings
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
February 18, 2026
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...
Via
StockStory
Topics
Stocks
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash
↗
February 18, 2026
Vertex has the revenue power to excel during any market environment.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
February 17, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based...
Via
Finterra
Topics
Economy
Intellectual Property
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
February 16, 2026
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly...
Via
MarketMinute
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
February 13, 2026
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a...
Via
StockStory
Topics
Economy
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026
↗
February 13, 2026
2026 could be a big year for this company.
Via
The Motley Fool
Top S&P500 movers in Friday's session
↗
February 13, 2026
Via
Chartmill
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)
↗
February 13, 2026
A sales partner offered a ray of hope that this company couldn't for itself.
Via
The Motley Fool
Friday's session: top gainers and losers in the S&P500 index
↗
February 13, 2026
Via
Chartmill
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
February 13, 2026
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Government
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase
February 13, 2026
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full...
Via
StockStory
Vertex (VRTX) Q4 2025 Earnings Call Transcript
↗
February 12, 2026
Vertex (VRTX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue
February 12, 2026
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full...
Via
StockStory
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect
February 10, 2026
Via
StockStory
Topics
Artificial Intelligence
World Trade
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell
↗
February 10, 2026
Vertex stock has climbed more than 60% over three years.
Via
The Motley Fool
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
